The following article has been retracted from publication in the Taylor & Francis journal Hematology:
Guray Saydam, Ibrahim C. Haznedaroglu, Leylagul Kaynar, Akif S. Yavuz, Ridvan Ali, Birol Guvenc, Olga M. Akay, Zafer Baslar, Ugur Ozbek, Mehmet Sonmez, Demet Aydin, Mustafa Pehlivan, Bulent Undar, Simten Dagdas, Orhan Ayyildiz, Diyar Z. Akkaynak, Gulnur Akin & Osman İlhan, Outcomes with frontline nilotinib treatment in Turkish patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase, Hematology, https://doi.org/10.1080/10245332.2018.1444919. Version of Record published online 27 February 2018.
The above article is being retracted as it it has been brought to the attention of the Editor and Managing Editor of Hematology that it was previously published as: Guray Saydam, Ibrahim Celalettin Haznedaroglu, Leylagul Kaynar, Akif S. Yavuz, Ridvan Ali, Birol Guvenc, Olga M. Akay, Zafer Baslar, Ugur Ozbek, Mehmet Sonmez, Demet Aydin, Mustafa Pehlivan, Bulent Undar, Simten Dagdas, Orhan Ayyildiz, Diyar Z. Akkaynak, Ilkiz M. Dag & Osman Ilhan “Outcomes With Frontline Nilotinib Treatment in Turkish Patients With Newly Diagnosed Philadelphia Chromosome–Positive Chronic Myeloid Leukemia in Chronic Phase” Expert Opinion on Pharmacotherapy, volume 17, issue 14, pages 1851-1858, doi: https://doi.org/10.1080/14656566.2016.1219338. The authors had intended to submit a follow-up article to Hematology but inadvertently submitted the same manuscript. The authors have agreed to the publication of this notice.
© Taylor & Francis